Carlyle Group Co-Founder And Co-Chairman David Rubenstein Joins Moderna's Board of Directors, Effective August 5, 2024 - Filing
Directors Robert Langer and Stephen Berenson will also retire from the Board.
Directors Robert Langer and Stephen Berenson will also retire from the Board.
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/13/2024 | $120.00 → $65.00 | Buy → Hold | Jefferies | |
9/13/2024 | $88.00 → $70.00 | Neutral → Underweight | JP Morgan | |
9/13/2024 | Outperform → Perform | Oppenheimer | ||
9/12/2024 | $42.00 | Equal Weight | Wells Fargo | |
8/28/2024 | $82.00 | Reduce → Hold | HSBC Securities | |
8/27/2024 | $55.00 | Buy | Redburn Atlantic | |
8/7/2024 | $85.00 → $80.00 | Sell → Hold | Deutsche Bank | |
8/6/2024 | $46.00 → $44.00 | Overweight → Neutral | JP Morgan |
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
SC 13D - Carlyle Group Inc. (0001527166) (Filed by)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
Jefferies downgraded Moderna from Buy to Hold and set a new price target of $65.00 from $120.00 previously
JP Morgan downgraded Moderna from Neutral to Underweight and set a new price target of $70.00 from $88.00 previously
Oppenheimer downgraded Moderna from Outperform to Perform
Sale simplifies Advance's enterprise structure and sharpens focus on the blended box business Net proceeds to be used primarily to strengthen balance sheet and invest in the business Advance Auto Parts, Inc. (NYSE:AAP), a leading automotive aftermarket parts provider in North America that serves both professional installer and do-it-yourself customers, announced that it has entered into a definitive agreement to sell Worldpac, Inc., an automotive parts wholesale distribution business, to funds managed by global investment firm Carlyle (NASDAQ:CG) for $1.5 billion in cash. The transaction is expected to close before the end of the year. "We are pleased to announce the sale of the World
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its second quarter ended June 30, 2024. Justin Plouffe, CGBD's Chief Executive Officer said, "Our core middle-market strategy and active approach to portfolio management continued to drive strong performance in the second quarter of 2024, as we maintained a dynamic approach to origination in an increasingly competitive market. With increased volume during the quarter, we capitalized on attractive origination opportunities, and we see the potential for increased deal ac
Provides meaningful scale and diversity to CGBD through addition of a Carlyle-managed portfolio Carlyle to exchange CGBD convertible preferred stock for CGBD common stock at NAV, eliminating current 5% – 8% preferred stock dilution overhang Advisors agreed to cover transaction costs in certain circumstances up to a total cap of $5 million NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD), a business development company focused on directly-originated lending to sponsor-backed U.S. middle market companies, has entered into a definitive agreement to acquire Carly
For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm
Ares Management Corp. (NYSE:ARES) and HPS Investment Partners are spearheading a $3 billion credit facility to finance Carlyle Group Inc.’s (NASDAQ:CG) potential acquisition of Baxter International Inc.’s (NYSE:BAX) kidney-care division. This debt package includes a $2.5 billion unitranche loan and a $450 million revolver. Oaktree Capital Management is also involved in the financing, and smaller lenders may participate after signing. Also Read: Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System. The financing terms suggest an interest rate five percentage points above the Secured Overnight Financing Rate, placing the division Vantive’s leverage at 4.2
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 42.19% on an annualized basis producing an average annual return of 54.8%. Currently, Moderna has a market capitalization of $45.66 billion. Buying $1000 In MRNA: If an investor had bought $1000 of MRNA stock 5 years ago, it would be worth $8,701.97 today based on a price of $119.13 for MRNA at the time of writing. Moderna's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and revie
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
8-K - Moderna, Inc. (0001682852) (Filer)
N-PX - Carlyle Group Inc. (0001527166) (Filer)
13F-HR - Carlyle Group Inc. (0001527166) (Filer)
Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive Phase 3 results for its RSV vaccine for high-risk adults aged 18 to 59; expects to submit sBLA for U.S. approval in 2024Announces positive Phase 3 results for its standalone flu vaccine for adults aged 65 and older relative to high-dose licensed comparatorAnnounces norovirus vaccine advances into Phase 3 study, bringing the total of non-respiratory pivotal stage programs to five, across oncology, rare diseases and first-in-class vaccinesImplements portfolio prioritization and cost efficiencies t
Altas Partners joins Carlyle and Stone Point Capital as strategic investors Investment will foster continued growth of global claims management provider MEMPHIS, Tenn., Sept. 12, 2024 /PRNewswire/ -- Sedgwick, a leading global provider of claims management, loss adjusting and technology-enabled business solutions, announced a strategic investment from Altas Partners ("Altas"), a North American private equity firm. Current investors, including funds managed by global investment firm Carlyle (NASDAQ:CG) and by Stone Point Capital LLC, will remain as investors and continue to make significant new investments in the business, with Carlyle maintaining its control position in partnership with the
Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collaboration Carisma is eligible to receive milestones and royalty payments PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (NASDAQ:CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the expansion of its in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") collaboration with Moderna, Inc. (NASDAQ:MRNA) to include the nomination of two targets for
London, UK and New York, USA, September 10, 2024 - Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ:CG), today announced the appointment of Robert (Bob) DeBenedetto as Managing Director – Clinical Co-Development. Bob brings to Abingworth over 30 years of experience in the life sciences industry and will be working on Clinical Co-Development deals and execution with new and existing Abingworth portfolio companies. He will be based in Abingworth's Menlo Park, CA, USA office. Prior to joining Abingworth, Bob was the Founder, President and CEO of SFJ Pharmaceuticals Inc. (CA, USA), an Abingworth portfolio company, where he
Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain, or improve people's health before they get sick. In its fifth year, the initiative is grounded in the premise that health should be accessible for all and pursues interventions that prot
MCLEAN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology solutions and clinical services company dedicated to helping government healthcare agencies accelerate better health outcomes, has named Brett Barton as Senior Vice President (SVP) of Client Experience. In this newly created role, Barton will represent the voice of the client across multiple touchpoints to deliver an exceptional experience that supports continued growth for the company and elevates the Acentra Health brand. Barton brings over three decades of experience in healthcare technology and services supporting the public sector and health and human services market. He comes to Acentra Health from Gainwell